IL158817A0 - Epf receptor assays, compounds and therapeutic compositions - Google Patents
Epf receptor assays, compounds and therapeutic compositionsInfo
- Publication number
- IL158817A0 IL158817A0 IL15881702A IL15881702A IL158817A0 IL 158817 A0 IL158817 A0 IL 158817A0 IL 15881702 A IL15881702 A IL 15881702A IL 15881702 A IL15881702 A IL 15881702A IL 158817 A0 IL158817 A0 IL 158817A0
- Authority
- IL
- Israel
- Prior art keywords
- epf
- assays
- compounds
- test compound
- therapeutic compositions
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pathology (AREA)
- Reproductive Health (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Pregnancy & Childbirth (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01202474 | 2001-06-27 | ||
PCT/EP2002/007263 WO2003005036A2 (en) | 2001-06-27 | 2002-06-26 | Epf receptor assays, compounds and therapeutic compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
IL158817A0 true IL158817A0 (en) | 2004-05-12 |
Family
ID=8180549
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15881702A IL158817A0 (en) | 2001-06-27 | 2002-06-26 | Epf receptor assays, compounds and therapeutic compositions |
IL158817A IL158817A (en) | 2001-06-27 | 2003-11-11 | Tests for FPE receptor, compounds and medical preparations |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL158817A IL158817A (en) | 2001-06-27 | 2003-11-11 | Tests for FPE receptor, compounds and medical preparations |
Country Status (17)
Country | Link |
---|---|
US (2) | US20040235722A1 (da) |
EP (1) | EP1399744B1 (da) |
JP (1) | JP4326326B2 (da) |
KR (2) | KR100971270B1 (da) |
CN (1) | CN100406891C (da) |
AT (1) | ATE397218T1 (da) |
AU (1) | AU2002317013B2 (da) |
CA (1) | CA2450502C (da) |
DE (1) | DE60226867D1 (da) |
DK (1) | DK1399744T3 (da) |
ES (1) | ES2307767T3 (da) |
HK (1) | HK1070694A1 (da) |
IL (2) | IL158817A0 (da) |
NO (1) | NO341778B1 (da) |
NZ (1) | NZ529714A (da) |
WO (1) | WO2003005036A2 (da) |
ZA (1) | ZA200309823B (da) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1340979A3 (en) * | 2002-02-27 | 2004-02-04 | Pfizer Limited | Neuropeptide receptor and uses thereof |
ATE520028T1 (de) | 2003-06-20 | 2011-08-15 | Discoverx Corp | Test zum nachweis von proteinbindung |
NZ566817A (en) | 2005-08-31 | 2012-02-24 | Cbio Ltd | Modified chaperonin 10, wherein the N-terminus comprises a single additional glycine residue compared to a corresponding mammalian wild-type |
CN101514335B (zh) | 2008-02-22 | 2013-04-17 | 中国科学院生物物理研究所 | 流感病毒聚合酶亚基pa的表达纯化及pa氨基端及pa羧基端与pb1氨基端多肽复合体的晶体结构 |
WO2009124353A1 (en) * | 2008-04-11 | 2009-10-15 | Cbio Limited | Modified cpn10 and prr signalling |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2233938T3 (es) * | 1993-11-30 | 2005-06-16 | The University Of Queensland | Chaperonina 10. |
US5989804A (en) * | 1994-07-08 | 1999-11-23 | New England Medical Center Hospitals, Inc. | E6 binding proteins |
SE9704836D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Pharma Inc | Novel receptor |
WO1999039208A1 (en) * | 1998-02-02 | 1999-08-05 | Concepto Diagnostics, Inc. | Method and apparatus for detecting conception in animals |
CN1379816A (zh) * | 1999-09-16 | 2002-11-13 | 索尔瓦药物有限公司 | 人g-蛋白偶联受体 |
WO2001036471A2 (en) * | 1999-11-17 | 2001-05-25 | Arena Pharmaceuticals, Inc. | Endogenous and non-endogenous versions of human g protein-coupled receptors |
-
2002
- 2002-06-26 DK DK02745422T patent/DK1399744T3/da active
- 2002-06-26 KR KR1020097019090A patent/KR100971270B1/ko active IP Right Grant
- 2002-06-26 KR KR1020037014859A patent/KR100977824B1/ko active IP Right Grant
- 2002-06-26 AT AT02745422T patent/ATE397218T1/de active
- 2002-06-26 EP EP02745422A patent/EP1399744B1/en not_active Expired - Lifetime
- 2002-06-26 JP JP2003510961A patent/JP4326326B2/ja not_active Expired - Fee Related
- 2002-06-26 DE DE60226867T patent/DE60226867D1/de not_active Expired - Lifetime
- 2002-06-26 AU AU2002317013A patent/AU2002317013B2/en not_active Ceased
- 2002-06-26 US US10/481,161 patent/US20040235722A1/en not_active Abandoned
- 2002-06-26 NZ NZ529714A patent/NZ529714A/en not_active IP Right Cessation
- 2002-06-26 CA CA2450502A patent/CA2450502C/en not_active Expired - Fee Related
- 2002-06-26 CN CN028131754A patent/CN100406891C/zh not_active Expired - Fee Related
- 2002-06-26 IL IL15881702A patent/IL158817A0/xx unknown
- 2002-06-26 ES ES02745422T patent/ES2307767T3/es not_active Expired - Lifetime
- 2002-06-26 WO PCT/EP2002/007263 patent/WO2003005036A2/en active Application Filing
-
2003
- 2003-11-11 IL IL158817A patent/IL158817A/en not_active IP Right Cessation
- 2003-12-18 ZA ZA2003/09823A patent/ZA200309823B/en unknown
- 2003-12-22 NO NO20035771A patent/NO341778B1/no not_active IP Right Cessation
-
2005
- 2005-04-19 HK HK05103348.8A patent/HK1070694A1/xx not_active IP Right Cessation
-
2006
- 2006-03-22 US US11/387,009 patent/US7402563B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
HK1070694A1 (en) | 2005-06-24 |
IL158817A (en) | 2012-01-31 |
ATE397218T1 (de) | 2008-06-15 |
KR100971270B1 (ko) | 2010-07-20 |
WO2003005036A2 (en) | 2003-01-16 |
US20040235722A1 (en) | 2004-11-25 |
KR20090111346A (ko) | 2009-10-26 |
EP1399744A2 (en) | 2004-03-24 |
CN1541335A (zh) | 2004-10-27 |
ES2307767T3 (es) | 2008-12-01 |
US20060160145A1 (en) | 2006-07-20 |
AU2002317013B2 (en) | 2007-11-01 |
NZ529714A (en) | 2008-04-30 |
CA2450502A1 (en) | 2003-01-16 |
JP2005503543A (ja) | 2005-02-03 |
ZA200309823B (en) | 2005-05-25 |
KR100977824B1 (ko) | 2010-08-25 |
DK1399744T3 (da) | 2008-09-22 |
NO20035771L (no) | 2004-02-26 |
KR20040010644A (ko) | 2004-01-31 |
JP4326326B2 (ja) | 2009-09-02 |
WO2003005036A3 (en) | 2003-10-16 |
CN100406891C (zh) | 2008-07-30 |
DE60226867D1 (de) | 2008-07-10 |
EP1399744B1 (en) | 2008-05-28 |
US7402563B2 (en) | 2008-07-22 |
CA2450502C (en) | 2017-10-31 |
NO341778B1 (no) | 2018-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006502416A5 (da) | ||
BR0306150A (pt) | Composto, uso de um composto, e, composição farmacêutica | |
CA2358938A1 (en) | Methods for assessing, improving, or maintaining urogenital health in postmenopausal women | |
DK1421389T3 (da) | Neurofibrilmarkører | |
EP1708745A4 (en) | ANTIBODIES FOR ONCOGEN STRAINS OF HPV AND METHODS OF USE | |
IL209509A0 (en) | Preimplantation factor peptide | |
HK1070694A1 (en) | Identification of a compound capable of binding to hdrr or capable of modulating hdrr activity using a epf receptor, and isolation of hdrr | |
WO2005103713A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
ZA200807766B (en) | Inhibition of GASC1 | |
DE60139770D1 (de) | Hydantoin derivate mit affinität für somatostatin rezeptoren | |
WO2003101176A3 (en) | Method, composition and kit for antigenic binding of norwalk-like viruses | |
Chansel et al. | Characterization of [3H] losartan receptors in isolated rat glomeruli | |
BR0308890A (pt) | Composto | |
DK1095275T3 (da) | Endogen, konstitutivt aktiverede G-protein-koblede orphan-receptorer | |
EP1582870A4 (en) | IMMUNOASSAY PROCEDURE AND KIT TO USE THEREOF | |
WO2002044368A1 (fr) | Nouvelles proteines du recepteur couple a la proteine g et leurs adn | |
WO2003089615A3 (en) | Antiviral inhibitions of capsid proteins | |
SE9904660D0 (sv) | Novel assays | |
WO2002075273A3 (en) | Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor | |
ATE408144T1 (de) | Assays | |
AU2001295423A1 (en) | Indirect method for the quantitative analysis of the binding capacity present in an aqueous protein solution | |
AU2003237702A1 (en) | Method for identifying agonists or antagonists for the g-protein coupled mas-like 1 receptor | |
Matsubara et al. | Evidence for the AT1 subtype of the angiotensin II receptor in the rat submandibular gland | |
WO2001068866A3 (en) | Estrogen-regulated unconventional myosin-related protein: compositions and methods of use |